Goal:
01 - Yoksulluğa Son

Loading...
Project Logo
Description
Yoksulluğun her biçiminin ortadan kaldırılması günümüzde insanlığın karşı karşıya olduğu en büyük sorun olmaya devam ediyor. Aşırı yoksulluk içinde yaşayan insanların sayısı 1990 ile 2015 arasında 1,9 milyardan 836 milyona düşmek suretiyle, yarıdan fazla azalmış olsa da, hala çok sayıda insan en temel insani gereksinimlerini karşılama savaşı vermektedir. Sürdürülebilir Kalkınma Amaçları, başlamış olduğumuz şeyi bitirme ve yoksulluğun her biçimi ve boyutunu ortadan kaldırma yönünde oldukça cesur bir taahhüttür. En korunmasız durumda olanların hedeflenmesi, temel kaynaklar ve hizmetlere erişimin artırılması ve çatışmalar ile iklim temelli afetlerden etkilenen toplumların desteklenmesini içerir.

Publication Search Results

Now showing 1 - 3 of 3
  • PublicationOpen Access
    Tobacco use among working adolescents and high school students in Turkey: evaluating the effect of the national tobacco control policy.
    (2021-01-01T00:00:00Z) Çakır, Erkan; Yazan, Hakan; Karacabey, Nazlı; Gedik, Ahmet Hakan; Özdemir, Ali; Varol, Nezih; Karakoç, Fazilet; Ersu, Refika; Karadağ, Bülent; Dağlı, Elif; ÇAKIR, ERKAN
  • PublicationOpen Access
    Recurrent Ischemic Stroke Characteristics and Assessment of Sufficiency of Secondary Stroke Prevention
    (2015-06-01) KOCAMAN, Gulsen; DURUYEN, Humeyra; Kocer, Abdulkadir; Asil, TALİP; ASİL, TALIP
    Introduction: Disabilities due to stroke lead to a serious individual and socioeconomic burden. In this presented hospital-based study, we aimed to evaluate recurrent ischemic stroke (RIS) characteristics and the sufficiency of secondary prevention regarding the most common modifiable risk factors. Methods: The records of patients with a diagnosis of ischemic stroke between November 2009 and November 2011 in our unit were retrospectively investigated. Results: Ninety-one (18%) out of 500 patients with ischemic stroke had RIS. Hypertension, diabetes mellitus, ischemic heart disease, hyperlipidemia, atrial fibrillation, and smoking were found in 88%, 43%, 36%, 30%, 11%, and 14% of the patients, respectively. Thirty-eight percent of the patients had more than two risk factors. While 14% of the hypertensive patients did not use antihypertensive medications, antihypertensive treatment was insufficient in 39% of those who already used antihypertensive medications. Twenty-three percent of the patients received no prophylactic agents. Sixty percent of the patients with a history of atrial fibrillation were on oral anticoagulant therapy (warfarin), and the international normalized ratio was <2.0 in 73% of them. Of the diabetic patients, 87% had an HgbA1C level above 6%. The LDL level was higher than 100 mg/dL in 72% of the patients. Conclusion: The incidence of RIS and risk factors in our retrospective study was compatible with the results of those in literature. Secondary prophylactic treatment and modification of risk factors in the stroke patients were not satisfactory. The improvement of the patients' adherence to treatment is also very important in addition to the optimal treatment and follow-up strategy for decreasing the incidence of RIS. A multidisciplinary outpatient model of stroke care may be beneficial for decreasing the incidence of RIS.
  • PublicationOpen Access
    Vitamin D Receptor Gene Haplotype Is Associated with Late-Onset Alzheimer-s Disease
    (2012-11-01T00:00:00Z) Gezen-Ak, Duygu; Dursun, Erdinc; Bilgic, Basar; Hanagasi, Hasmet; Ertan, Turan; Gurvit, Hakan; Emre, Murat; Eker, Engin; Ulutin, Turgut; Uysal, Omer; Yilmazer, Selma; UYSAL, ÖMER
    Vitamin D-3 is a neurosteroid that mediates its effects via the vitamin D receptor (VDR). The VDR gene is located on chromosome 12q13 and consists of 9 exons. VDR contains the DNA-binding site encoded by exons 2 and 3 and the ligand-binding site encoded by exons 4 - 9. Our earlier study showed that the ApaI polymorphic site of the VDR gene is associated with late-onset Alzheimer-s disease (AD). Here, we investigated the association between additional polymorphisms of the VDR gene and AD using the same samples. Two single nucleotide polymorphisms (SNPs) in intron 8 (BsmI and Tru9I polymorphisms) and one in exon 2 (FokI polymorphism) of the VDR gene were examined in up to 108 AD patients and 115 age-matched controls. Genotypes were determined with polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods. Haplotype analysis also included the previously studied polymorphic sites that were recognized by TaqI (in exon 9) and ApaI (in intron 8) restriction enzymes. There was no significant difference between AD patients and controls when their genotypes for BsmI, Tru9I and FokI polymorphic sites were compared. However, the frequency of -TaubF- haplotype (alleles of TaqI, ApaI, Tru9I, BsmI and FokI, respectively), which was determined by analyzing 5 polymorphisms together, was significantly higher in the AD patient group, suggesting that this haplotype is a risk factor in AD. Our results point out a possible link between AD and certain VDR polymorphisms and indicate that individuals with these polymorphisms might be vulnerable to AD.